The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Ankylosing Spondylitis Resource Center
    • Gout Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / EULAR 2013: Research Hints at Risk Factors for Rheumatoid Arthritis

EULAR 2013: Research Hints at Risk Factors for Rheumatoid Arthritis

September 1, 2013 • By Thomas R. Collins

  • Tweet
  • Email
Print-Friendly Version / Save PDF

The line of inquiry stems from the idea that “we have a therapeutic window of opportunity. Although we don’t know when it exactly starts and when it finishes, we have a feeling that when you treat patients that are diagnosed with rheumatoid arthritis, actually in the first few months after the disease, that we can be more effective in reaching remission and preventing erosions,” Dr. Gerlag said. An extension of that idea is that there is also a “preventive window of opportunity.”

You Might Also Like
  • Rheumatoid Arthritis Research Provides New Insights on Risk Factors, Identification Tools, Intervention
  • Genetic Risk Factors for Rheumatoid Arthritis Merit More Research
  • 2013 ACR/ARHP Annual Meeting: Genetic Research Yields Clues to Pathogenesis of Rheumatoid Arthritis, Psoriatic Arthritis
Explore This Issue
September 2013
Also By This Author
  • DADA2 Research Reveals Mechanisms & Possible Gene Therapy

One study at her center is looking at just how often people at high risk end up developing RA without treatment. So far, a cohort of 55 people, either with rheumatoid factor (IgM-RF) or who are ACPA-positive, has been followed for as long as 47 months. To date, 15 people, or 27%, have developed RA, and they have a follow-up range of 6 months to 27 months, with an average of 13 months.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Researchers also found that those with a BMI of 25 or higher, and who smoked at some point in their lives, had a hazard ratio of disease development of 7.5 compared to three other groups: those who have smoked and had a BMI of lower than 25, and those who have never smoked and had a BMI above or below 25.

In PRAIRI (Prevention of RA by Rituximab), researchers are planning to follow for four years patients with a high risk of developing RA. Their hope is that a 1,000-mg dose of the drug in the preclinical phase of the disease will help delay or prevent the development of RA.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

So far, 95 patients have been enrolled, with 74 getting the medication. Sixteen, or 21%, have developed arthritis, with the average follow-up of six months until clinical arthritis developed.

“I think that prevention is better than cure and that the true window of opportunity is the preventive window of opportunity,” Dr. Gerlag said. “The question remains, of course, who do we treat, when do we treat them, and how do we treat them?”


Thomas Collins is a freelance medical writer based in Florida.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

Pages: 1 2 3 | Single Page

Filed Under: Conditions, Meeting Reports, Rheumatoid Arthritis Tagged With: anti-CCP antibodies, citrullinated targets, EULAR 2013, Research, Rheumatoid arthritisIssue: September 2013

You Might Also Like:
  • Rheumatoid Arthritis Research Provides New Insights on Risk Factors, Identification Tools, Intervention
  • Genetic Risk Factors for Rheumatoid Arthritis Merit More Research
  • 2013 ACR/ARHP Annual Meeting: Genetic Research Yields Clues to Pathogenesis of Rheumatoid Arthritis, Psoriatic Arthritis
  • Bronchial Tissue Immune Activation Seen in Early Rheumatoid Arthritis

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2021 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.